MedTrace Logo

Assessing the Effects of the Muse Meditation System on Cognition and Well-being

NCT04790929 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-07-25

No results posted yet for this study

Summary

Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. What is not known, is whether the use of the Muse devices can improve cognitive function. In this study, the investigators will examine whether use of the Muse Meditation system by healthy participants, leads to improvements in cognition, sleep quality, mindfulness, improvement in quality of life scores, reduction in perceived stress levels, and improvement in cognitive markers relevant for safety and increased success in the workplace.

Conditions

  • Cognitive Change

Interventions

DEVICE

Muse

Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.

BEHAVIORAL

Meditation Coaching

Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.

Sponsors & Collaborators

  • InteraXon, Inc.

    collaborator INDUSTRY

  • Cambridge Brain Sciences

    collaborator INDUSTRY

  • Western University, Canada

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-05-01
Completion
2022-12-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790929 on ClinicalTrials.gov